Compare DNN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | AAPG |
|---|---|---|
| Founded | 1954 | 2009 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1997 | 2025 |
| Metric | DNN | AAPG |
|---|---|---|
| Price | $3.31 | $27.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | ★ 41.4M | 4.7K |
| Earning Date | 11-06-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,493,456.00 | ★ $54,524,554.00 |
| Revenue This Year | $197.29 | N/A |
| Revenue Next Year | $55.12 | $368.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.35 | N/A |
| 52 Week Low | $1.08 | $16.50 |
| 52 Week High | $3.42 | $48.45 |
| Indicator | DNN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 71.40 | 48.72 |
| Support Level | $2.61 | $26.00 |
| Resistance Level | $2.81 | $28.40 |
| Average True Range (ATR) | 0.15 | 0.64 |
| MACD | 0.07 | 0.29 |
| Stochastic Oscillator | 78.27 | 72.83 |
Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.